Biomark Diagnostics (BMKDF, $0.14) was a top loser over the last three months, falling to $0.14 per share. A.I.dvisor analyzed 416 stocks in the Medical Specialties Industry for the 3-month period ending December 30, 2024, and found that of them (4) exhibited an Uptrend while of them (5) demonstrated a Downtrend.